Bicara Therapeutics Relocates Offices

TL;DR

Bicara Therapeutics moved its HQ to Boston, MA.

AI Summary

Bicara Therapeutics Inc. filed an 8-K on September 16, 2024, reporting a change in its principal executive offices to 116 Huntington Avenue, Suite 703, Boston, MA 02116, effective September 12, 2024. The company also updated its telephone number to 617-468-4219.

Why It Matters

A change in executive offices can indicate growth, consolidation, or strategic shifts within a company. Investors should monitor if this move impacts operations or costs.

Risk Assessment

Risk Level: low — This filing primarily concerns administrative changes like office relocation and contact information updates, which typically carry low risk.

Key Players & Entities

• Bicara Therapeutics Inc. (company) — Registrant
• September 12, 2024 (date) — Effective date of change
• September 16, 2024 (date) — Filing date
• 116 Huntington Avenue, Suite 703, Boston, MA 02116 (location) — New principal executive offices
• 617-468-4219 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share BCAX The Nasdaq

Filing Documents

• d844648d8k.htm (8-K) — 19KB
• d844648dex31.htm (EX-3.1) — 29KB
• d844648dex32.htm (EX-3.2) — 120KB
• 0001193125-24-219617.txt ( ) — 169KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 BICARA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-42271 85-2903745 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Bicara Therapeutics Inc. 116 Huntington Avenue, Suite 703 Boston, MA 02116 (Address of principal executive offices, including zip code) 617-468-4219 (Registrants telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAX The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.03 Amendments to Articles of Incorporation or Bylaws. As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-281722) (the Registration Statement), of the Company, and in connection with the completion of the IPO, the Company filed its fifth amended and restated certificate of incorporation (the Amended and Restated Certificate) with the Secretary of State of the State of Delaware. The Companys board of directors (the Board) and the Companys stockholders previously approved the Amended and Restated Certificate to be filed in connection with, and to be effective immediately prior to, the completion of the IPO. The Amended and Restated Certificate amends and restates the Companys existing fourth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series. The foregoing description of the Amended and Restated Certificate is qualified by reference to the Amended and Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. In addition, as previously disclosed in the Registration Statement, the third amended and restated bylaws of the Company (the Amended and Restated Bylaws), previously approved by the Board and the Companys stockholders, became effective as of the effectiveness of the Registration Statement. The Amended and Restated Bylaws amend and restate the Companys bylaws in their entirety to, among other things: (i) eliminate the ability of the Companys stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate. The foregoing description of the Amended and Restated Bylaws is qualified by reference to the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference. Item9.01 Financial Statements and Exhibits. (d) Exhibits 3.1 Fifth Amended and Restated Certificate of Incorporation of Bicara Therapeutics Inc. 3.2 Third Amended and Restated Bylaws of Bicara Therapeutics Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bicara Therapeutics Inc. Date: September 16, 2024

View Full Filing

View this 8-K filing on SEC EDGAR